Atisama Therapeutics (formerly Rage Bio), an Australian clinical-stage biotechnology company, on Friday reported progress in the Phase 1 study of its lead candidate, RB042.

The RB042 Phase 1 study (RB042_1001), evaluating RB042 in healthy volunteers and healthy smokers, has advanced to multi-dose ascending (MAD) cohorts, and continues to demonstrate safety and tolerability, Atisama said.

Three of four single ascending dose (SAD) cohorts are complete, and the first MAD cohort has been initiated, with higher-dose cohorts expected to readout in the second half of 2026.

RB042 is an inhaled splice-switching oligonucleotide (SSO) targeting the Receptor for Advanced Glycation End-products (RAGE), a genetically validated driver of inflammation in chronic obstructive pulmonary disease (COPD).